Barclays Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $21.00

Celldex Therapeutics (NASDAQ:CLDX) had its target price cut by Barclays from $25.00 to $21.00 in a research report released on Tuesday,Benzinga reports. They currently have an underweight rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $62.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, September 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Mizuho started coverage on shares of Celldex Therapeutics in a report on Tuesday, October 21st. They set an “outperform” rating and a $48.00 target price for the company. Citigroup dropped their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research report on Wednesday, August 20th. Finally, Wells Fargo & Company reduced their price target on Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.80.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $23.72 on Tuesday. The stock has a market capitalization of $1.58 billion, a P/E ratio of -7.88 and a beta of 1.36. Celldex Therapeutics has a 52 week low of $14.40 and a 52 week high of $29.05. The stock has a fifty day moving average of $25.51 and a 200-day moving average of $22.82.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. Equities research analysts forecast that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

A number of large investors have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd acquired a new stake in Celldex Therapeutics during the 3rd quarter worth $26,000. Nisa Investment Advisors LLC increased its holdings in shares of Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 881 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Celldex Therapeutics during the third quarter worth about $42,000. Russell Investments Group Ltd. lifted its holdings in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Celldex Therapeutics in the 3rd quarter valued at approximately $63,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.